Take combination chemotherapy with different schedules for newly diagnosed blood cancer

Back to Newly Diagnosed Multiple Myeloma trials

What is this trial?

This trial is testing a new approach to treating newly diagnosed multiple myeloma, a blood cancer affecting plasma cells in the bone marrow. The study compares two different schedules for giving (a targeted antibody therapy) along with other standard chemotherapy drugs. The goal is to find out whether patients do better with a longer upfront treatment phase or a shorter one followed by a stem cell transplant.

Multiple myeloma is a serious blood cancer, but newer drugs have greatly improved outcomes. Doctors want to figure out the best way to give these newer medications—specifically, whether more intensive initial treatment followed by transplant is better than extended chemotherapy without transplant, and whether this medication can reduce the need for transplant altogether.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with multiple myeloma that has not been treated yet
you have measurable disease (detectable protein or light chains in your blood or urine)
you have low-risk disease based on specific genetic testing (R-ISS stage I)
you are between 18 and 70 years old
you are in good enough health to receive high-dose chemotherapy and stem cell transplant
you have adequate veins or vascular access for blood collection and stem cell collection

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use contraception during treatment
you have high-risk genetic features in your myeloma cells
you are unable to attend regular study visits or follow the treatment schedule
you have other serious medical conditions that would make intensive chemotherapy unsafe

What participation looks like

Participants will receive intravenous chemotherapy infusions over several months as part of one of two treatment groups. Group A receives 3 cycles of induction therapy, then proceeds to stem cell collection and a high-dose chemotherapy cycle with stem cell transplant. Group B receives 3 cycles of induction therapy, stem cell collection, then 3 more cycles of chemotherapy without transplant. Both groups then receive ongoing maintenance therapy with the medication to help prevent the cancer from coming back. The trial involves regular clinic visits for blood tests, imaging scans, and monitoring for side effects.

Two treatment schedules for newly diagnosed blood cancer patients

What is this trial?

Do you qualify?

What participation looks like

Trial locations(6 sites)